Glenmark Pharmaceuticals, a global pharmaceutical company, today presented findings from a Phase 2a study of GBR 830, an investigational anti-OX40 monoclonal antibody, at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego.

The GBR 830 Phase 2a study was a double-blind, placebo-controlled study in adults with moderate-to-severe atopic dermatitis (AD) that evaluated the safety, biological and clinical activity, and pharmacokinetics of GBR 830.

''We are pleased to share detailed findings from this study, which indicate that GBR 830 is well-tolerated and has demonstrated biological response,'' said Fred Grossman, President and Chief Medical Officer at Glenmark Pharmaceuticals. ''Novel, selective biologic therapies like GBR 830 hold great promise in the treatment of AD, and Glenmark is committed to rigorous further study of its mechanism and potential for clinical efficacy.''

Shares of the company declined Rs 2, or 0.38%, to trade at  Rs 519.80.  The total volume of shares traded  was  16,541 at the BSE (9.58 a.m., Monday).